Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus
Methodological detailsmulti-disciplinary, anonymous online Delphi questionnaire, virtual consensus meeting, ACCORD reporting
- Multi-disciplinary
- Anonymous online Delphi questionnaire
- Virtual consensus meeting
- ACCORD reporting
Recommendations
As issued by the authors
Diabetic retinopathy (DR) worsening events are primarily linked to rapid blood glucose-lowering, rather than a direct drug effect
Benefits of GLP-1 RAs outweigh potential ocular risks and should not limit access to these medicines
Screen people with diabetes for DR before starting GLP-1 RAs, particularly high-risk populations (>10 years duration and/or poor glucose control, HbA1c >10% or 86 mmol/mol)
When prescribing GLP-1 RA to those with sight loss in one eye and/or prior NAION, discuss the risk of ocular complications
Original publication
Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus. Diabetes Obes Metab. Published 8 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →